Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of two drugs, inebilizumab and blinatumomab, in adults with active and treatment-resistant autoimmune diseases, including systemic lupus erythematosus SLE with nephritis and rheumatoid arthritis RA. This Phase 2 trial includes several subprotocols to study these medications in different patient groups and disease conditions. Participants may receive inebilizumab through intravenous infusions in either three or four doses, or blinatumomab via subcutaneous injections at low, medium, or high doses. The trial includes parts where doses are determined based on earlier results. The treatments are studied in subgroups of patients with SLE with or without nephritis and in patients with active refractory RA. Throughout the study, participants will be monitored for treatment-emergent adverse events and serious adverse events up to 52 weeks. Various clinical measures for kidney response, disease remission, and disease activity scores will be assessed at multiple time points. Safety, drug levels, antibody formation, and disease activity changes will be tracked regularly, with a total study duration extending up to 52 weeks for outcome evaluations.
Actively Recruiting
Researchers are studying the safety, tolerability, and preliminary effects of a single infusion of ICG318 in people with refractory Systemic Lupus Erythematosus SLE, with or without Lupus Nephritis LN. SLE is a chronic autoimmune disease affecting multiple organs, and LN is a severe form of SLE affecting the kidneys. This Phase IIa open-label, single-arm study focuses on patients who have not responded adequately to prior therapies. Participants will first undergo a lymphodepletion treatment and then receive a single infusion of ICG318, an investigational chimeric antigen receptor CAR therapy designed to target specific B cells and plasma cells involved in SLE. The study includes an initial safety run-in followed by dose expansion to assess the recommended Phase 2 dose. The treatment involves a biologic drug infusion. During the study, participants will be closely monitored for adverse events up to one year after infusion. Researchers will measure disease activity, remission rates, kidney function, autoantibody levels, and immune cell recovery through blood tests, kidney biopsies, and other assessments. The total duration of participation includes treatment and follow-up evaluations extending to one year to understand safety and clinical responses.
Actively Recruiting
Researchers are evaluating the safety and tolerability of different doses of a nebulized treatment called KB407 in adults with cystic fibrosis, a genetic condition affecting the lungs. This is a Phase 1 study sponsored by Krystal Biotech, Inc., focusing on how well adults with cystic fibrosis tolerate this new inhaled therapy designed to deliver a functional version of the CFTR protein. Participants will receive KB407 through inhalation in one of several dosing schedules a single dose, two doses, four doses, or four consecutive doses followed by weekly doses up to six months. The study includes four open-label groups, each receiving different administration frequencies to assess safety and potential effects over time. During the study, participants will undergo evaluations of adverse events, physical exams, vital signs, ECGs, and laboratory tests over six months to monitor safety and tolerability. Researchers will also measure lung function changes using forced expiratory volume in one second FEV1. Participants will be closely monitored to track any side effects and changes in lung health throughout the treatment period and follow-up.
Actively Recruiting
This trial evaluates the combination of Navlimetostat BMS-986504, pembrolizumab, and chemotherapy compared to placebo with pembrolizumab and chemotherapy in adults with first-line metastatic non-small cell lung cancer having homozygous MTAP deletion. The study is a randomized, double-blind Phase 23 trial sponsored by Bristol-Myers Squibb, aiming to understand treatment benefits in this specific patient group. Participants must have measurable metastatic NSCLC, no prior systemic therapy for metastatic disease, and meet performance status criteria. Participants receive either Navlimetostat plus pembrolizumab and chemotherapy or placebo plus pembrolizumab and chemotherapy. Chemotherapy may include drugs such as cisplatin, carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel, given on specified days at specified doses. Treatment is administered in the first-line metastatic setting, with detailed dosing and combinations determined by study protocols. Randomization assigns participants to one of multiple arms to compare the investigational combination against placebo. Throughout the study, participants are monitored for progression-free survival up to 2 years and 5 years, overall survival up to 5 years, as well as response rates and safety outcomes including adverse events and laboratory abnormalities. Assessments follow RECIST v1.1 criteria with independent and investigator reviews. Safety monitoring includes tracking serious adverse events and treatment-related side effects up to 90 days after treatment ends. The study duration extends to the primary completion date in August 2031, with ongoing evaluations for up to 5 years post-treatment.
Actively Recruiting
Researchers are comparing the effects of two treatment combinations in adults with stage IV or recurrent non-squamous non-small cell lung cancer NSCLC that has a PD-L1 expression of 1% or higher. This phase 3 trial investigates whether Nivolumab and Relatlimab combined with chemotherapy works differently than Pembrolizumab with chemotherapy as first-line treatment for this condition. The study is sponsored by Bristol-Myers Squibb and uses a randomized parallel design. Participants will be assigned to one of two groups one group receives Nivolumab and Relatlimab with chemotherapy drugs, while the other group receives Pembrolizumab with chemotherapy. Chemotherapy may include drugs such as Carboplatin, Pemetrexed, or Cisplatin, given at specified doses on specific days. Treatment schedules and doses are carefully planned, and participants are treated during the trial period. During the study, participants undergo regular assessments to measure overall survival, progression-free survival, response rates, and duration of response, with follow-up lasting up to five years. Researchers also track adverse events and immune-related side effects for up to 2.5 years. Quality of life is monitored through symptom questionnaires. Assessments include imaging scans and laboratory tests to evaluate disease status and treatment effects. The total duration of participation may extend over several years to capture long-term outcomes and safety.
Actively Recruiting
Researchers are evaluating the effects of cannabidiol oral solution CBD-OS on focal-onset seizures in participants aged 12 to 75 years. This phase 1b open-label study aims to assess how CBD-OS reduces seizure frequency and impacts health outcomes in both early line and treatment-resistant focal seizure patients. The study also investigates safety, pharmacokinetics, and factors influencing treatment response through brain imaging and neuropsychological tests in a substudy. Participants will receive open-label CBD-OS according to the approved local dosing guidelines. The study monitors participants who are on stable antiseizure medication regimens, and treatment response will be compared to baseline seizure frequency. This trial is designed as a single-group study without placebo or comparator arms. During the study, participants will have their focal seizure counts tracked and compared to baseline over a period of up to 16 weeks. Evaluations include safety assessments, pharmacokinetic sampling, functional MRI, and neuropsychological testing for a subset of participants. The total study duration spans from screening through treatment and monitoring until study completion, with ongoing safety and efficacy evaluations.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of JZP926 capsules for treating Juvenile Myoclonic Epilepsy JME in participants aged 10 years and older. This Phase 23 study is randomized, placebo-controlled, and double-blind, focusing on how well JZP926 reduces the number of days with myoclonic seizures compared to a placebo. The study also examines other effects of JZP926 beyond seizure control. Participants will be randomly assigned to receive either JZP926 capsules or matching placebo capsules based on their body weight. The treatment period lasts 16 weeks, with doses given twice daily. After completing this phase, participants may opt to join an open-label extension of up to 52 weeks, which includes a 4-week blinded transition period, allowing all participants to receive JZP926. During the study, participants will have regular assessments to track seizure frequency and other health measures. This includes monitoring myoclonic seizure days, other seizure types, and patient or caregiver impressions of daily activities. Blood samples will be collected to measure drug and metabolite levels. Safety is monitored throughout, and the primary outcome is the change in myoclonic seizure days over the 16-week treatment. The total study duration may extend up to about 68 weeks for those in the extension phase.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tezepelumab in children aged 5 to under 12 years with severe uncontrolled asthma who are already using medium to high doses of inhaled corticosteroids and at least one other asthma controller medication, with or without oral corticosteroids. This phase 3, multicenter, randomized, double-blind study aims to compare tezepelumab with a placebo to better understand its impact on asthma control in this age group. Participants will be randomly assigned in a 21 ratio to receive either subcutaneous injections of tezepelumab or a matching placebo over a 52-week double-blind treatment period. Before treatment, there is a 4 to 6 week screening and run-in period. After the treatment period, a 12-week off-treatment follow-up occurs for those not continuing. Eligible participants may enter an optional 104-week open-label extension to receive tezepelumab with an additional 12-week follow-up after that. During the study, participants will undergo various assessments including lung function tests, asthma symptom tracking, quality of life questionnaires, and blood tests to measure biomarkers and drug levels. Researchers will monitor asthma exacerbations, rescue medication use, and healthcare visits. Safety will be closely observed throughout the study and follow-up periods. Total participation may last over two years for those in the extension phase.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and tolerability of a new multivalent pneumococcal vaccine called PG4 in healthy infants. The study compares this new vaccine to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC to see how well they protect against infections like pneumonia, meningitis, and ear infections caused by Streptococcus pneumoniae. The trial is a Phase 3, randomized, double-blinded study involving about 2400 infants around 2 months old. Participants will be randomly assigned to receive either the new PG4 vaccine or the 20vPnC vaccine. Both vaccines are given as injections into the left thigh muscle at 2, 4, 6, and between 12 to 15 months of age. The study lasts about 16 to 19 months, during which infants will have six clinic visits and one phone call to monitor their health and any side effects. During these visits, parents or legal guardians will report any local reactions, systemic events, or other adverse effects experienced by the infant after each vaccine dose. Researchers will track events occurring within seven days after each dose, as well as serious adverse events up to six months following the last dose. The goal is to understand the safety profile of the new vaccine compared to the existing one over the course of the study period.
Actively Recruiting
This research aims to evaluate the long-term safety and tolerability of brivaracetam in children and adolescents with epilepsy, including those who participated in earlier studies or are newly enrolled in Japan with partial-onset seizures. The study also seeks to assess pharmacokinetic data in Japanese participants. The study is an open-label, single-arm, multicenter trial focusing on pediatric epilepsy treatment with brivaracetam. Participants will receive brivaracetam tablets or oral solution administered twice daily in two equal doses. Dosage varies based on weight up to 5 mgkgday for those weighing 11 to less than 20 kg, up to 4 mgkgday for those weighing 20 to less than 50 kg, and no more than 200 mgday. Directly enrolled participants in Japan will receive 1 to 4 mgkgday, not exceeding 200 mgday. The study includes long-term follow-up for up to 5 years. During the study, participants will be monitored for treatment-emergent adverse events, serious adverse events, and adverse events leading to discontinuation of the drug. Evaluations occur from Day 1 through safety visits over the 5-year period. Researchers will assess safety, tolerability, and pharmacokinetics. The total participation duration extends up to 5 years, with ongoing safety evaluations throughout this time.
1-10 of 15
1